Tirzepatide is a novel once-weekly glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP-1/GPL-1) receptor dual agonist, which recently has been approved as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes [156,157]. This evidence concerns the gene GIP and type 2 diabetes mellitus.